• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia

byConstance Wu
October 14, 2019
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this randomized controlled trial, oral lefamulin was noninferior to oral moxifloxacin for treating community-acquired pneumonia, with regards to early clinical response at 96 hours post first dose.

2. Patients who received lefamulin reported more diarrhea and nausea than those who received moxifloxacin.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The rate of microbial resistance is growing among patients suffering from community acquired bacterial pneumonia (CABP). As a result, new antibiotics are required to overcome this resistance and further help manage the outstanding safety concerns. Lefamulin, a novel pleuromutilin antibiotic, is the first of its class to be approved for enteral or parenteral use in humans. In this randomized controlled trial, a 5-day oral lefamulin course was shown to be noninferior to a 7-day oral moxifloxacin course. Both medications were reported to produce a high clinical response with respect to Pneumonia Outcomes Research Team (PORT) risk class, typical and atypical pathogens, polymicrobial infections, and demographic and baseline characteristics at 96 hours post first dose. In addition, there were similar rates of adverse events between groups, though there were more episodes of diarrhea and nausea in the lefamulin group.

The study successfully randomized a high proportion of patients with more severe forms of CABP, limited use of prior antibiotics, and demonstrated low drug and study discontinuation rates, which strengthens the trial findings. The trial is limited by its extensive exclusion criteria, which restricts the results from being applied to the general patient population with comorbid diseases.

Click to read the study in JAMA

Click to read an accompanying editorial in JAMA

RELATED REPORTS

Lower dose and shorter duration of amoxicillin treatment noninferior to higher dose and longer treatment in children with community-acquired pneumonia

#VisualAbstract: Male sex and older age are independently associated with treatment failure after antibiotic treatment of community-acquired pneumonia

Male sex and older age are independently associated with treatment failure after antibiotic treatment of community-acquired pneumonia

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: community acquired pneumonialefamulinmoxifloxacinpleuromutilin
Previous Post

Further evidence of racial disparities in adolescent suicidal behavior

Next Post

2 Minute Medicine Rewind October 14, 2019

RelatedReports

X-ray after foreign body removal by esophagoscopy is not cost effective
Emergency

Lower dose and shorter duration of amoxicillin treatment noninferior to higher dose and longer treatment in children with community-acquired pneumonia

November 3, 2021
#VisualAbstract: Male sex and older age are independently associated with treatment failure after antibiotic treatment of community-acquired pneumonia
StudyGraphics

#VisualAbstract: Male sex and older age are independently associated with treatment failure after antibiotic treatment of community-acquired pneumonia

October 28, 2021
Prescription of antibiotics for acute respiratory infections increasing
Emergency

Male sex and older age are independently associated with treatment failure after antibiotic treatment of community-acquired pneumonia

October 21, 2021
Updated review confirms efficacy and safety of most standard treatments for latent tuberculosis infection
Chronic Disease

Rifapentine-moxifloxacin noninferior to standard of care treatment for pulmonary tuberculosis

May 10, 2021
Next Post
2 Minute Medicine Rewind October 14, 2019

2 Minute Medicine Rewind October 14, 2019

Quick Take: Safety and Efficacy of Ozanimod Versus Interferon Beta-1a in Relapsing Multiple Sclerosis (SUNBEAM)

Quick Take: Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis

Quick Take: Effect of Collaborative Dementia Care via Telephone and Internet on Quality of Life, Caregiver Well-Being, and Health Care Use

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early onset Lewy Body Dementia is more clinically distinct from Alzheimer Dementia than late onset Lewy Body Dementia
  • Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
  • Operating the day after performing surgery the previous night not associated with adverse patient outcomes
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.